Breast cancer drugs stop working when tumours ‘make their own fuel’

Google+ Pinterest LinkedIn Tumblr +

Breast cancerScientists have discovered why a type of breast cancer drug stops working in some patients.

The early-stage findings, from an international team led by Imperial College London and the European Institute of Oncology in Milan, reveal some breast tumours evolve to make their own ‘fuel supply’, rendering treatments powerless.

The team, whose findings are published in the journal Nature Genetics, hope their work will increase treatment options for patients whose cancer has returned.

Around 70 per cent of breast cancers are so-called ER positive, which means the cancer cells contain a receptor for the hormone estrogen. It is this hormone that fuels the tumours.

Patients with this type of cancer are offered one of two drugs after surgery to prevent the cancer coming back.

One of these drugs, tamoxifen, prevents estrogen from binding to DNA in cancer cells, while the second type of treatment, aromatase inhibitors, prevents residual estrogen from being produced in other tissues.

The latter drugs are usually used in women who have gone through the menopause. These women’s ovaries have stopped producing estrogen, but some of the hormone is still made in several other tissues by an enzyme called aromatase. The medication prevents this enzyme making estrogen.

However both tamoxifen and aromatase inhibitors stop working in around one in three patients.

Scientists assumed the tumours developed resistance in some way, but didn’t know how.

However in the latest study, the team discovered that in one in four patients taking aromatase inhibitors, the tumours had increased production of aromatase in the cancer cells. The tumours appear to do this by increasing the number of aromatase genes, in a process called amplification.

This allowed the cancer cells to effectively make their own estrogen, without relying on external sources of the hormone, explained Dr Luca Magnani, co-lead author of the research from the Department of Surgery and Cancer at Imperial: “For the first time we have seen how breast cancer tumours become resistant to aromatase inhibitors. The treatments work by cutting off the tumour’s fuel supply — estrogen — but the cancer adapts to this by making its own fuel supply.”

observe woman watchful waiting active surveillance worry anxiety_oncology news australiaThe researchers also discovered that tumours become resistant in different ways, depending on whether tamoxifen or aromatase inhibitors are used.

Almost none of the tumours in patients taking tamoxifen had increased production of aromatase to boost their estrogen supply – and the team are now planning further studies into how cancer cells become resistant to tamoxifen.

In the current research the team analysed tumour samples taken from 150 women whose breast cancer had returned and spread around the body. All the women were treated at the European Institute of Oncology in Milan.

The team are now working on a test to identify whether a patient’s tumour has started to increase aromatase production, and make its own estrogen.

“In many cases when an aromatase inhibitor stops working in a patient, doctors will try another type of aromatase inhibitor. However, our research suggests that if the patient’s cancer has started to make their own aromatase, this second drug would be useless. This is why we need a test to identify these patients,” added Dr Magnani.

Dr Magnani added that, in the meantime, doctors should take a second sample of the tumour, called a biopsy, when the cancer returns.

“At the moment, patients often only have one biopsy, when they are first diagnosed. However, if they had a second biopsy when the cancer returns, this will give us vital information about how the cancer has evolved and the treatment options available.”

He hoped this study may lead to more options for patients whose breast cancer has returned or spread.

“Once a cancer spreads, the disease is incurable. However, let’s not give up this fight too soon – if we take a second biopsy we can find out which treatments would work. Around half of breast cancers are diagnosed in women over 65, which means that with treatment advances we may be able to make breast cancer a chronic disease, and enable people to reach a normal life expectancy.”


SourceImperial College London
Paper: Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, Giacomo Corleone, Sonia Fabris, Mannus H Kempe, Pernette J Vershure, Iros Barozzi, Valentina Vircillo, Sung-Pil Hong, Ylenia Perone, Massimo Saini, Andreas Trumpp, Giuseppe Viale, Antonino Neri, Simak Ali, Marco Angelo Colleoni, Giancarlo Pruneri, Saverio Minucci. Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. Nature Genetics, 2017; DOI: 10.1038/ng.3773

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Comments are closed.